Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-26-032694
Filing Date
2026-03-20
Accepted
2026-03-20 16:05:49
Documents
19
Period of Report
2026-05-01

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A tm261499-3_def14a.htm   iXBRL DEF 14A 607915
6 GRAPHIC bc_comptsr-4c.jpg GRAPHIC 57837
7 GRAPHIC bc_netincome-4c.jpg GRAPHIC 53724
8 GRAPHIC lg_markertherapeutics-4clr.jpg GRAPHIC 31700
9 GRAPHIC px_26markertheproxy1pg01-bw.jpg GRAPHIC 327875
10 GRAPHIC px_26markertheproxy1pg02-bw.jpg GRAPHIC 234633
  Complete submission text file 0001104659-26-032694.txt   2977402

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrkr-20251231.xsd EX-101.SCH 7987
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrkr-20251231_def.xml EX-101.DEF 3606
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrkr-20251231_lab.xml EX-101.LAB 25730
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrkr-20251231_pre.xml EX-101.PRE 6096
24 EXTRACTED XBRL INSTANCE DOCUMENT tm261499-3_def14a_htm.xml XML 87211
Mailing Address 2450 HOLCOMBE BLVD TMC PARTNERS OFFICE 1.311 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD TMC PARTNERS OFFICE 1.311 HOUSTON TX 77021 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37939 | Film No.: 26778271
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)